US · Healthcare · Medical Devices
EPS came in at -0.31 against a street estimate of -0.34 — a beat of 8.8%.
Analysts rate Tandem Diabetes Care Inc a buy (14 buy, 11 hold, 0 sell out of 25) with an average price target of $27.86.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.65% |
| Sessa Capital, L.P | 7.33% |
| Vanguard Portfolio Management, LLC | 6.18% |
| First Light Asset Management, LLC | 4.86% |
| Vanguard Capital Management, LLC | 4.45% |
| State Street Corp | 4.10% |
| GW&K Investment Management, LLC | 3.69% |
| Jennison Associates LLC | 3.35% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 TANDEM DIABETES CARE, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6M 2026): $501.8 million vs. $475.1 million (6M 2025) — up 5.6% • Reve | 2026-08-06 |
| Results announced · Q3 2026 TANDEM DIABETES CARE, INC. — Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Sales: $254.6 million worldwide (up 6% YoY); U.S. sales $179.3 mill | 2026-08-06 |
| Board / officer change · Q2 2026 TANDEM DIABETES CARE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 20, 2026 with 57,964,375 shares present or represented by p | 2026-05-21 |
| Board / officer change · Q2 2026 TANDEM DIABETES CARE, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Mark Novara, Executive Vice President and Chief Commercial Officer, em | 2026-05-15 |
| Quarterly report · Q1 2026 TANDEM DIABETES CARE, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Sales: $247.2 million (vs. $234.4 million Q1 2025, +5.5% growth) • Q1 2 | 2026-05-07 |
| Results announced · Q2 2026 TANDEM DIABETES CARE Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Sales: $247.2 million worldwide (up 5% vs. Q1 2025), comprised of $160.8 million US | 2026-05-07 |
| Proxy statement · Q4 2025 TANDEM DIABETES CARE, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors for one-year terms (Board recomme | 2026-04-07 |
| Annual report FY2025 TANDEM DIABETES CARE, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $1.3 billion • S | 2026-02-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tandem Diabetes Care Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.